WallStreetZenWallStreetZen

NASDAQ: OMER
Omeros Corp Stock

$4.09+0.12 (+3.02%)
Updated Jun 24, 2024
OMER Price
$4.09
Fair Value Price
N/A
Market Cap
$236.70M
52 Week Low
$0.92
52 Week High
$5.84
P/E
-2.07x
P/B
-3.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$121.30M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-7.13
Operating Cash Flow
-$142M
Beta
1.21
Next Earnings
Aug 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

OMER Overview

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OMER scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

OMER is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OMER is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
OMER's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more OMER due diligence checks available for Premium users.

Be the first to know about important OMER news, forecast changes, insider trades & much more!

OMER News

Valuation

OMER fair value

Fair Value of OMER stock based on Discounted Cash Flow (DCF)
Price
$4.09
Fair Value
-$0.00
Undervalued by
111,981.44%
OMER is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

OMER price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.07x
Industry
-6.96x
Market
30.03x

OMER price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-3.32x
Industry
6.29x

OMER's financial health

Profit margin

Revenue
$0.0
Net Income
-$37.2M
Profit Margin
0%
OMER's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$437.5M
Liabilities
$508.8M
Debt to equity
-7.13
OMER's short-term assets ($280.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OMER's long-term liabilities ($449.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OMER's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OMER's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$41.8M
Investing
-$61.9M
Financing
$98.4M
OMER's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

OMER vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
OMER$236.70M+2.90%-2.07x-3.32x
MOLN$236.33M-25.10%-3.68x1.28x
CBUS$236.02M-4.40%-0.38x0.85x
SKYE$235.77M+8.11%-3.59x2.99x
RENB$234.53M+1.27%-2.04x1.39x

Omeros Stock FAQ

What is Omeros's quote symbol?

(NASDAQ: OMER) Omeros trades on the NASDAQ under the ticker symbol OMER. Omeros stock quotes can also be displayed as NASDAQ: OMER.

If you're new to stock investing, here's how to buy Omeros stock.

What is the 52 week high and low for Omeros (NASDAQ: OMER)?

(NASDAQ: OMER) Omeros's 52-week high was $5.84, and its 52-week low was $0.92. It is currently -30.05% from its 52-week high and 344.02% from its 52-week low.

How much is Omeros stock worth today?

(NASDAQ: OMER) Omeros currently has 57,944,159 outstanding shares. With Omeros stock trading at $4.09 per share, the total value of Omeros stock (market capitalization) is $236.70M.

Omeros stock was originally listed at a price of $8.73 in Oct 8, 2009. If you had invested in Omeros stock at $8.73, your return over the last 14 years would have been -53.21%, for an annualized return of -5.28% (not including any dividends or dividend reinvestments).

How much is Omeros's stock price per share?

(NASDAQ: OMER) Omeros stock price per share is $4.09 today (as of Jun 24, 2024).

What is Omeros's Market Cap?

(NASDAQ: OMER) Omeros's market cap is $236.70M, as of Jun 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Omeros's market cap is calculated by multiplying OMER's current stock price of $4.09 by OMER's total outstanding shares of 57,944,159.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.